Shan, Sun <br/><br/>
New evidences for fractalkine/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson's disease.  [electronic resource] 

 -  Neurobiology of aging  Mar 2011 
 - 443-58 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1558-1497 
<br/><br/><label>Standard No.: </label>10.1016/j.neurobiolaging.2009.03.004  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine--adverse effects<br/>Analysis of Variance<br/>Animals<br/>Antibodies--pharmacology<br/>Antiparkinson Agents--pharmacology<br/>Apomorphine--pharmacology<br/>Chemokine CX3CL1--adverse effects<br/>DNA Nucleotidylexotransferase--pharmacology<br/>Disease Models, Animal<br/>Dose-Response Relationship, Drug<br/>Drug Interactions<br/>Gene Expression Regulation--drug effects<br/>Levodopa--pharmacology<br/>Male<br/>Mental Disorders--etiology<br/>Nerve Tissue Proteins--metabolism<br/>Parkinson Disease--complications<br/>Rats<br/>Rats, Sprague-Dawley<br/>Reaction Time--drug effects<br/>Stereotyped Behavior--drug effects<br/>Substantia Nigra--metabolism<br/>Tyrosine 3-Monooxygenase--metabolism